Test Your Knowledge: ASCO 2020 Quiz

1) The Phase 3 CASPIAN Trial met its primary endpoint of overall survival, reducing the risk of death by 27% in newly diagnosed patients with ES-SCLC after more than 2 years by combining durvalumab (Imfinzi) with what:*

durvalumab + tremelimumab
durvalumab + tremelimumab + etoposide cisplatin/carboplatin
durvalumab + etoposide cisplatin/carboplatin
durvalumab + placebo

2) At 18 months, of the patients who received durvalumab plus chemotherapy vs placebo in the CASPIAN Phase 3 Trial, 34% were alive vs 25%, respectively.*

True
False

3) What trial showed that adjuvant treatment with osimertinib (Tagrisso) reduced the risk of disease recurrence or death by 79% in patients with stage IB to IIIA EGFR-mutant NSCLC?*

ADAURA
KEYNOTE
CHECKMATE
CITYSCAPE

4) Phase 3 CHECKMATE-227 found that patients with advanced NSCLC treated with nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy had a 21% reduced risk of death after a median follow up of about*

13 months
25 months
43 months
51 months

5) Data from phase 3 KEYNOTE-604 showed patients with ES-SCLC who received pembrolizumab (Keytruda) with chemotherapy improved overall survival vs chemotherapy and placebo.*

True
False

Claim Your Free Staff Education Wallboard!

Please select specialty

Test Your Knowledge: ASCO 2020 Quiz

Leave a Reply Cancel reply

Meeting Coverage

Claim Your Free
Staff Education Wallboard!